Portal de Periódicos da CAPES

Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience

2020; Taylor & Francis; Volume: 61; Issue: 13 Linguagem: Inglês

10.1080/10428194.2020.1802452

1042-8194

Elisabetta Antonioli, Michela Staderini, Sofia Pilerci, Federico Perfetto, Francesco Cappelli, Marco Allinovi, Chiara Nozzoli, Irene Attucci, Alessandra Buzzichelli, Maria Messeri, Alberto Bosi,

Peptidase Inhibition and Analysis

In recent years, the clinical outcome of multiple myeloma (MM) patients has improved due to the introduction of several new agents and of immunotherapy. The combination of novel drugs has allowed i...